Babiker T, Vedovato N, Patel K, Thomas N, Finn R, Männikkö R, Chakera AJ, Flanagan SE, Shepherd MH, Ellard S, Ashcroft FM, Hattersley AT.

Wellcome Trust , PDA/02/06/098 Department of Health

             regulation of insulin secretion

Fig. 1. Sulfonylurea block of wild-type and mutant KATP channels. Percentage inhibition of whole-cell KATP channel currents in wild-type (WT) and mutant (as indicated) channels in response to 0.5 mmol/l tolbutamide. Current in the presence of tolbutamide is expressed as a percentage of that in the absence of drug [2, 9, 11–14]. The numbers in parenthesis indicate the number of patients who responded to sulfonylureas (left) out of the total number (right) with the indicated mutation. White bars, all patients responded; grey bars, some patients responded; black bars, no patients responded. The vertical light grey bar indicates the level of block that separates those patients who responded from those who did not

Fig. 2. The younger the patients are (i.e. the shorter the duration of diabetes), the greater the likelihood of a successful transfer. Only KCNJ11 mutations for which some patients transfer and others do not (p.R201H, p.R201C, p.V59M, p.G334C, p.G53S, p.Q52R) are shown. White bars, successful transfer; black bars, unsuccessful transfer

Brereton, Reversible changes in pancreatic islet structure and function produced by elevated blood glucose. 2014, Pubmed

Brereton, Reversible changes in pancreatic islet structure and function produced by elevated blood glucose. 2014, Pubmed
Flanagan, Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype. 2006, Pubmed
Gillis, Effects of sulfonamides on a metabolite-regulated ATPi-sensitive K+ channel in rat pancreatic B-cells. 1989, Pubmed
Girard, Functional analysis of six Kir6.2 (KCNJ11) mutations causing neonatal diabetes. 2006, Pubmed , Xenbase
McTaggart, The role of the KATP channel in glucose homeostasis in health and disease: more than meets the islet. 2010, Pubmed
Mlynarski, Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11. 2007, Pubmed
O'Connell, The value of in vitro studies in a case of neonatal diabetes with a novel Kir6.2-W68G mutation. 2015, Pubmed
Pearson, Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. 2006, Pubmed , Xenbase
Shimomura, Adjacent mutations in the gating loop of Kir6.2 produce neonatal diabetes and hyperinsulinism. 2009, Pubmed
Shimomura, Mutations at the same residue (R50) of Kir6.2 (KCNJ11) that cause neonatal diabetes produce different functional effects. 2006, Pubmed , Xenbase
Thurber, Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11-related neonatal diabetes. 2015, Pubmed